Novozymes closes streptococcal based production of hyaluronic acid
The facility in the Shandong Province, China, for streptococcal based production of hyaluronic acid (sHA) was originally acquired by Novozymes in early 2006 as an addition to Novozymes' existing bacillus based hyaluronic acid (bHA) production.
Novozymes is now closing the facility because of adverse market developments. In particular, accelerating price erosion for sHA in the dietary supplement market coupled with a low growth outlook in technical markets has meant that the commercial assumptions behind the acquisition can no longer be met. The decision will have no significant financial impact for Novozymes, according to the company. The facility employs a total of 132 employees. Novozymes will as far as possible help all employees when the facility closes.
Most read news
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.